Barclays analyst Benjamin Budish raised the firm’s price target on CME Group to $228 from $226 and keeps an Equal Weight rating on the shares. The company’s Q1 earnings beat by 1%, driven by both better than expected revenues and lower than expected costs, and the tone of the call was positive, the analyst tells investors in a research note.